Logo image of DNAD

SOCIAL CAPITAL SUVRETTA HO-A (DNAD) Stock Fundamental Analysis

USA - NASDAQ:DNAD - KYG8253Y1052 - Common Stock

10.35 USD
+0.01 (+0.1%)
Last: 6/30/2023, 4:00:19 PM
Fundamental Rating

2

Overall DNAD gets a fundamental rating of 2 out of 10. We evaluated DNAD against 0 industry peers in the Unkown industry. While DNAD seems to be doing ok healthwise, there are quite some concerns on its profitability. DNAD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year DNAD was profitable.
In the past year DNAD has reported a negative cash flow from operations.
DNAD Yearly Net Income VS EBIT VS OCF VS FCFDNAD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 0 1M -1M 2M

1.2 Ratios

Industry RankSector Rank
ROA 2.11%
ROE 2.17%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DNAD Yearly ROA, ROE, ROICDNAD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 0 0.2 -0.2 0.4 0.6 0.8 1

1.3 Margins

DNAD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNAD Yearly Profit, Operating, Gross MarginsDNAD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022

More info and screens

6

2. Health

2.1 Basic Checks

DNAD has about the same amout of shares outstanding than it did 1 year ago.
There is no outstanding debt for DNAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DNAD Yearly Shares OutstandingDNAD Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 10M 20M 30M
DNAD Yearly Total Debt VS Total AssetsDNAD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

DNAD has an Altman-Z score of 25.02. This indicates that DNAD is financially healthy and has little risk of bankruptcy at the moment.
DNAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 25.02
ROIC/WACCN/A
WACCN/A
DNAD Yearly LT Debt VS Equity VS FCFDNAD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 0 50M 100M 150M 200M

2.3 Liquidity

DNAD has a Current Ratio of 1.01. This is a normal value and indicates that DNAD is financially healthy and should not expect problems in meeting its short term obligations.
DNAD has a Quick Ratio of 1.01. This is a normal value and indicates that DNAD is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 1.01
DNAD Yearly Current Assets VS Current LiabilitesDNAD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 200K 400K 600K 800K

More info and screens

1

3. Growth

3.1 Past

DNAD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 830.86%, which is quite impressive.
EPS 1Y (TTM)830.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1280.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 60.88, which means the current valuation is very expensive for DNAD.
The average S&P500 Price/Earnings ratio is at 27.40. DNAD is valued rather expensively when compared to this.
Industry RankSector Rank
PE 60.88
Fwd PE N/A
DNAD Price Earnings VS Forward Price EarningsDNAD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNAD Per share dataDNAD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DNAD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOCIAL CAPITAL SUVRETTA HO-A

NASDAQ:DNAD (6/30/2023, 4:00:19 PM)

10.35

+0.01 (+0.1%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.8%
Inst Owner Change-44.07%
Ins Owners2.01%
Ins Owner Change0%
Market Cap330.06M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 60.88
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB 1.33
EV/EBITDA N/A
EPS(TTM)0.17
EY1.64%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS7.8
TBVpS7.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.11%
ROE 2.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.01
Quick Ratio 1.01
Altman-Z 25.02
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)830.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1280.12%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y71.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y71.89%
OCF growth 3YN/A
OCF growth 5YN/A